Lutris Pharma
3 known investors
Lutris Pharma is a clinical-stage biopharmaceutical company developing LUT014, a topical B-RAF inhibitor gel intended to reduce acneiform rash and other skin side effects caused by cancer therapies such as EGFR and RAS inhibitors. It serves cancer patients and aims to help them stay on their treatments by mitigating skin toxicity.
Investors · 3
In the news
Frequently asked questions
- What does Lutris Pharma do?
- Lutris Pharma is a clinical-stage biopharmaceutical company developing LUT014, a topical B-RAF inhibitor gel intended to reduce acneiform rash and other skin side effects caused by cancer therapies such as EGFR and RAS inhibitors. It serves cancer patients and aims to help them stay on their treatments by mitigating skin toxicity.
- Who are Lutris Pharma's investors?
- Lutris Pharma's investors include aMoon, Peregrine Ventures, Pontifax Venture Capital.